Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GOT1 | P17174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421171 | 0.77 | NOS3 (0.50) | ALDH1A1MAPTKDM4EBRD4GAA | |
| SCHEMBL20265503 | 0.74 | ALDH1A1 (0.34) | ALDH1A1MAPTKDM4EBRD4GAA | |
| SCHEMBL12704677 | 0.74 | MAPT (0.43) | ALDH1A1MAPTKDM4EBRD4GAA | |
| SCHEMBL31200409 | 0.74 | RAB9A (0.46) | ALDH1A1MAPTKDM4EBRD4RAB9A | |
| SCHEMBL4204986 | 0.74 | RAB9A (0.46) | ALDH1A1MAPTKDM4EBRD4RAB9A | |
| SCHEMBL8180922 | 0.70 | — | — | |
| SCHEMBL21939937 | 0.70 | TDP1 (0.30) | TDP1 | |
| SCHEMBL8136374 | 0.69 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4ETDP1GAA | |
| SCHEMBL9919116 | 0.69 | — | — | |
| SCHEMBL331473 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CDKN1A, CDC25C, DDB1 | ALDH1A1 788/4885MAPT 4288/4885KDM4E 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.